Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) Shares Outstanding (Weighted Average) (2019 - 2025)

Historic Shares Outstanding (Weighted Average) for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $72.6 million.

  • C4 Therapeutics' Shares Outstanding (Weighted Average) rose 421.69% to $72.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.6 million, marking a year-over-year increase of 421.69%. This contributed to the annual value of $69.4 million for FY2024, which is 3975.08% up from last year.
  • Per C4 Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $72.6 million for Q3 2025, which was up 421.69% from $71.0 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $72.6 million in Q3 2025 and a low of $43.1 million during Q1 2021
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $49.1 million (2023), whereas its average is $56.0 million.
  • In the last 5 years, C4 Therapeutics' Shares Outstanding (Weighted Average) surged by 304689.27% in 2021 and then soared by 49.14% in 2023.
  • C4 Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $46.0 million in 2021, then grew by 6.12% to $48.9 million in 2022, then grew by 1.59% to $49.6 million in 2023, then surged by 39.75% to $69.4 million in 2024, then increased by 4.6% to $72.6 million in 2025.
  • Its last three reported values are $72.6 million in Q3 2025, $71.0 million for Q2 2025, and $70.8 million during Q1 2025.